Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review ; volume:38 ; number:2 ; day:11 ; month:1 ; year:2021 ; pages:969-993 ; date:2.2021
Advances in therapy ; 38, Heft 2 (11.1.2021), 969-993, 2.2021
- Creator
-
Cella, David
Evans, Jennifer
Feuilly, Marion
Neggers, Sebastian
Genechten, Dirk Van
Herman, Jackie
Khan, Mohid S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-020-01600-x
- URN
-
urn:nbn:de:101:1-2021040702381000669516
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cella, David
- Evans, Jennifer
- Feuilly, Marion
- Neggers, Sebastian
- Genechten, Dirk Van
- Herman, Jackie
- Khan, Mohid S.
- SpringerLink (Online service)
Other Objects (12)
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management
Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management
Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management
Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment